Prana Biotechnology Limited (PRAN)
-NasdaqCM | Prev Close: | 3.77 |
|---|
| Open: | N/A |
|---|
| Bid: | N/A |
|---|
| Ask: | N/A |
|---|
| 1y Target Est: | 6.00 |
|---|
| Beta: | N/A |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | N/A - N/A |
|---|
| 52wk Range: | 1.81 - 6.50 |
|---|
| Volume: | 0 |
|---|
| Avg Vol (3m): | 769,306 |
|---|
| Market Cap: | 146.90M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | N/A |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Prana Biotechnology slumps on delay for drug dataAP(Fri, Sep 13)
- Prana Updates Progress on PBT2 Trials in Alzheimer's and Huntington's DiseasesMarketwired(Fri, Sep 13)
- Parkinson's UK Awards GBP 150,000 to Study Prana's PBT434Marketwired(Wed, Sep 4)
- Prana Drug Treatment PBT2 Named One of Top Neuroscience Projects to WatchMarketwired(Tue, Sep 3)
- The Past, Present, and Future of Alzheimer’s Treatmentsat Motley Fool(Fri, Aug 23)
- Prana Prepares for Next Steps in the PBT2 Development Path to Market and Commercialization With Key Appointments StrategyMarketwired(Thu, Aug 1)
- 4 Healthcare Stock Stories Causing Commotion On Mondayat Wall St. Cheat Sheet(Mon, Jul 29)
- Prana Doses First Patient in PBT2 Alzheimer's Extension StudyMarketwired(Mon, Jul 29)
- Prana Completes Phase 2 Huntington Disease Trial With PBT2Marketwired(Tue, Jul 23)
- Prana rises on extension of Alzheimer's drug studyAP(Wed, Jul 3)
- Prana Receives Approval for 12-Month Open-Label Extension Study in Alzheimer's DiseaseMarketwired(Wed, Jul 3)
- Prana PBT 434 drug candidate shows potential in tratment in Parkinson's Diseasetheflyonthewall.com(Thu, Jun 20)
- PBT434 Drug Candidate Shows Potential as "Next-Generation" Disease-Modifying Treatment in Parkinson's DiseaseMarketwired(Thu, Jun 20)
- Prana Presents New Benchmark Test to Assess Huntington's Disease Patients in Clinical TrialsMarketwired(Wed, Jun 19)
- Prana Announces Share Purchase Plan ClosedMarketwired(Fri, May 3)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 30.89 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Jun-13)
: | -0.03 |
|---|
| Quarterly EPS Est
(0-00-31)
: | N/A |
|---|
| Mean Recommendation*: | 2.0 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Prana Biotechnology Limited researches and develops therapeutic drugs for the treatment of neurological disorders in Australia. It primarily focuses on the Alzheimers, Parkinsons, and Huntingtons diseases, as well as various canc...
View More
0.41%